Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

STRATA Skin Sciences (SSKN) Long-Term Debt Issuances (2014 - 2021)

STRATA Skin Sciences recorded quarterly Long-Term Debt Issuances of $8.0 million in Q3 2021, up 216.46% quarter-over-quarter from $2.5 million in Q4 2020, and up 416.46% year-over-year from $1.5 million in Q3 2020.

STRATA Skin Sciences' Long-Term Debt Issuances history runs 6 years deep, the most recent figure standing at $8.0 million for Q3 2021.

  • In Q3 2021, Long-Term Debt Issuances rose 416.46% year-over-year to $8.0 million; the TTM figure through Dec 2022 stood at $8.0 million (changed 0.0% YoY), while the FY2023 annual figure was $7.0 million, changed N/A from the prior year.
  • Long-Term Debt Issuances came in at $8.0 million for Q3 2021 at STRATA Skin Sciences, up from $2.5 million in the prior quarter.
  • In the past five years, Long-Term Debt Issuances ranged from a high of $8.0 million in Q3 2021 to a low of -$2.5 million in Q3 2020.
  • A 3-year average of $3.8 million and a median of $4.9 million in 2019 frame the typical range for Long-Term Debt Issuances.
  • Across the five-year window, Long-Term Debt Issuances tumbled 65.25% in 2020 and jumped 416.46% in 2021, its largest moves.
  • STRATA Skin Sciences' Long-Term Debt Issuances stood at $7.3 million in 2019, then sank by 65.25% to $2.5 million in 2020, then soared by 216.46% to $8.0 million in 2021.
  • According to Business Quant data, Long-Term Debt Issuances over the past three periods registered $8.0 million, $2.5 million, and -$2.5 million for Q3 2021, Q4 2020, and Q3 2020 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Issuances (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 19.86 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn 11.71 Mn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn 1.15 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn -
10 STRATA Skin Sciences - - 5.61 Mn -

Historic Data

Download Data 🔒
DateValue
Sep 30, 2021 8.00 Mn
Sep 30, 2021 8.00 Mn
Dec 31, 2020 2.53 Mn
Dec 31, 2020 2.53 Mn
Sep 30, 2020 -2.53 Mn
Sep 30, 2020 -2.53 Mn
Dec 31, 2019 7.28 Mn
Dec 31, 2019 7.28 Mn
Mar 31, 2016 1.50 Mn
Mar 31, 2016 1.50 Mn
Jun 30, 2015 10.00 Mn
Jun 30, 2015 10.00 Mn
Sep 30, 2014 -11.45 Mn
Sep 30, 2014 -11.45 Mn